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ABSTRACT
Despite reductions in mortality from the use of highly active antiretroviral therapy 
(HAART), the presence of latent or transcriptionally silent proviruses prevents HIV 
cure/eradication. We have previously reported that DNA-dependent protein kinase 
(DNA-PK) facilitates HIV transcription by interacting with the RNA polymerase II 
(RNAP II) complex recruited at HIV LTR. In this study, using different cell lines and 
peripheral blood mononuclear cells (PBMCs) of HIV-infected patients, we found that 
DNA-PK stimulates HIV transcription at several stages, including initiation, pause-
release and elongation. We are reporting for the first time that DNA-PK increases 
phosphorylation of RNAP II C-terminal domain (CTD) at serine 5 (Ser5) and serine 
2 (Ser2) by directly catalyzing phosphorylation and by augmenting the recruitment 
of the positive transcription elongation factor (P-TEFb) at HIV LTR. Our findings 
suggest that DNA-PK expedites the establishment of euchromatin structure at HIV 
LTR. DNA-PK inhibition/knockdown leads to the severe impairment of HIV replication 
and reactivation of latent HIV provirus. DNA-PK promotes the recruitment of Tripartite 
motif-containing 28 (TRIM28) at LTR and assists the release of paused RNAP II 
through TRIM28 phosphorylation. These results provide the mechanisms through 
which DNA-PK controls the HIV gene expression and, likely, can be extended to 
cellular gene expression, including during cell malignancy, where the role of DNA-PK 
has been well-established.
INTRODUCTION
Combination anti-retroviral therapy (cART), 
commonly known as highly active antiretroviral 
therapy (HAART), is able to suppress replication of 
human immunodeficiency virus (HIV) quite effectively, 
oftentimes with a single daily dose. However, even 
after several years of undetectable viremia, the virus 
resurrects out of latent reservoirs and quickly re-emerges 
in circulation if HAART is interrupted [1, 2]. Thus, the 
presence of latent or transcriptionally silent HIV provirus 
is a major hurdle to HIV eradication. The persistence of 
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HIV in patients, despite prolonged treatment, has renewed 
interest in understanding the molecular mechanisms that 
control HIV life cycle. It is well accepted that the state 
of HIV transcription dictates the prevalence of either 
productively replicating or latent HIV proviruses in the 
cells [3–8]. The bigger pool of latent proviruses consists 
of defective HIV progeny, which are incompetent in 
generating fully functional HIV [9, 10]. However, 
defective proviruses can still transcribe their genes and 
produce some of the viral proteins that contribute to 
HIV-mediated cytotoxicity [11]. Therefore, thorough 
understanding of the mechanisms that regulate HIV 
transcription is a prerequisite for effectively applying any 
strategy for HIV eradication or a functional cure.
Analogous to host gene transcription, HIV 
transcription is regulated by the well-controlled 
phosphorylation events of the carboxyl-terminal domain 
(CTD) of the largest subunit of the RNA polymerase II 
(RNAP II) [12]. The mammalian RNAP II CTD consists 
of 52 tandem repeats of a consensus sequence Tyr1-
Ser2-Pro3-Thr4-Ser5-Pro6-Ser7 [13, 14]. More than 
half a dozen kinases are known to phosphorylate CTD 
of RNAP II. Among these, the importance of cyclin-
dependent kinases (mainly CDK7 for phosphorylation 
of Serine 5 (Ser5), and CDK9 for phosphorylation of 
Serine 2 (Ser2)) during HIV transcription has already 
been established [12, 13, 15]. We recently discovered 
that the DNA-dependent protein kinase (DNA-PK) is 
another kinase that phosphorylates the CTD of RNAP 
II and plays an important role during HIV transcription. 
Previously, we had documented the parallel presence of 
DNA-PK along with RNAP II throughout the HIV proviral 
genome during HIV transcription [16]. By performing in 
vitro kinase assays, we showed that DNA-PK is able to 
phosphorylate all three serine residues (Ser2, Ser5, and 
Ser7) of the CTD region of RNAP II. We found that 
the transactivator of transcription (Tat) protein, which 
is vital for HIV transcription, is a potential substrate of 
DNA-PK. The finding that cellular activation enhances 
nuclear translocation of DNA-PK and its activation further 
supports our observation of greater DNA-PK recruitment 
at HIV long terminal repeat (LTR) following cellular 
activation [16, 17].
The human DNA-PK is a nuclear kinase that 
specifically requires association with DNA for its 
activity [18–21]. DNA-PK holoenzyme consists of two 
components: a 450 kDa catalytic subunit (DNA-PKcs) 
[22], which is a serine/threonine kinase, and a regulatory 
component known as Ku [23]. Ku is a heterodimer 
comprised of two subunits, one 70 kDa [24] and another 
80 kDa [25]. The 70 kDa subunit possesses ATPase and 
DNA helicase activities. The vital role of DNA-PK in 
the non-homologous end joining (NHEJ) DNA-repair 
pathway is well-recognized [26, 27].
HIV transcription pauses after transcribing around 
first 60 bp [28, 29]. RNAP II pausing is mainly attributed 
to the binding of negative elongation factor (NELF) and 
DRB sensitivity-inducing factor (DSIF) to HIV LTR 
[28, 30]. Later, the Tat protein, by recruiting positive 
transcription elongation factor b (P-TEFb), relieves 
RNAP II pausing [31, 32]. The CDK9 subunit of P-TEFb 
phosphorylates the NELF and DSIF subunits, which either 
converts them to a positive elongation factor or removes 
them from LTR [3]. Transcriptional elongation needs the 
sequential specific phosphorylation events at RNAP II 
CTD in order to transform RNAP II to an elongating or 
processive enzyme.
Phosphorylation of Ser5 residue of the RNAP 
II CTD is linked to the initiation phase of transcription 
[33, 34], whereas phosphorylation of Ser2 is found to 
be correlated with the elongation phase of transcription, 
also during HIV gene expression [28, 35, 36]. In addition 
to DSIF and NELF, another factor, the tripartite motif-
containing 28 (known as TRIM28, KAP1, TIF1β), 
has been shown recently to support RNAP II pausing 
at certain cellular genes [37–39]. Similar to the SPT5 
subunit of DSIF [40], the phosphorylation of TRIM28 
converts it from a pausing or negative elongation factor 
to a positive elongation factor [39, 41]. DNA-PK is the 
principal kinase which directly interacts with TRIM28 
and catalyzes the phosphorylation of TRIM28 at serine 
824 residue converting it to an elongation factor [39]. 
Pertaining HIV transcription, the role of TRIM28 is still 
not clear. However, the presence of TRIM28 bound with 
7SK snRNP complex at HIV LTR has been documented 
[42], and the role of TRIM28 during HIV latency has 
also been proposed [43]. In addition to ours [16], other 
studies have also noted the interaction between RNAP II 
and DNA-PK [44]. Moreover, we have shown that DNA-
PK is a component of RNAP II holoenzyme, recruited 
at HIV LTR, and it rides along RNAP II throughout the 
HIV genome [16]. Recently, the interaction of TRIM28 
with RNAP II and the continuous presence of TRIM28 
with RNAP II along cellular genes’ body have been 
documented [38, 39]. In our investigation, by attenuating 
the activity or cellular levels of DNA-PK, we have 
established the role of DNA-PK not only in activating 
TRIM28 through phosphorylation, but also in recruiting 
TRIM28 and phosphorylated TRIM28 (p-TRIM28, S824) 
at HIV LTR.
Several studies focusing on cancer therapy have 
targeted DNA-PK with small molecule inhibitors [45–47] 
in efforts to kill cancerous cells through accumulation of 
unrepaired DNA breaks induced by ionizing radiation 
[48, 49]. For this purpose, several DNA-PK inhibitors 
have been developed. Early inhibitors, which include 
1-(2-hydroxy-4-morpholin-4-yl-phenyl)-ethanone (known 
as IC86621), suppressed DNA-PK activity by reversibly 
inhibiting its ATP binding. IC86621 was proved to be a 
clinically effective DNA-PK inhibitor [50]. Subsequently, 
a more specific, class of DNA-PK inhibitors, including 
LY294002, was developed that binds selectively to the 
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kinase domain of DNA-PK [51]. Later, LY294002 became 
the template for the development of even more specific 
DNA-PK inhibitors, such as NU7026 (2-(morpholin-4-yl)-
benzo-H-chromen-4-one) which was shown to be 50-fold 
more specific for DNA-PK than other kinases [52, 53]. 
One more related compound, NU7441 (2-N-(morpholino-
8-benzothiophenyl)-chromen-4-one), was found to be 
even more selective for DNA-PK than NU7026 [45, 54–
56]. These highly specific, non-toxic competitive DNA-
PK inhibitors induce phenotype similar to that of DNA-PK 
deficient cell line and DNA-PK knockout mice [45, 56]. 
The use of these inhibitors severely restricts DNA double-
strand break (DSB) repair, a primary activity of DNA-PK, 
and enhances the cytotoxicity of physical and chemical 
agents that induce DSB formation, such as ionizing 
radiation. Consequently, these inhibitors are being utilized 
as anti-cancer agents in several preclinical and phase-I 
clinical studies [45, 56–59].
In a prior publication, we suggested an important role 
of DNA-PK during HIV transcription, and documented 
the continuous presence and gliding of DNA-PK with 
RNAP II along the HIV genome during transcription [16]. 
In the current study, we sought to evaluate the mechanism 
through which DNA-PK promotes HIV transcription, 
replication, and latent proviral reactivation. We explored 
the impact on HIV gene expression after inhibition or 
depletion of endogenous DNA-PK, by treating cells with 
either specific inhibitors or specific shRNA, respectively. 
We assessed the impact of DNA-PK on the phosphorylation 
state of RNAP II CTD and on the regulation of epigenetic 
changes at HIV LTR. The results were confirmed in various 
cell types belonging to different lineages, including the 
physiologically relevant primary T cells and cells from HIV-
infected patients. We found that DNA-PK plays a major role 
during HIV transcription by supporting it at multiple steps. 
Consequently, DNA-PK inhibition or removal drastically 
impairs HIV transcription, replication, and reactivation 
of latent provirus. In latently infected cells, where HIV 
provirus is transcriptionally silent, we noted highly reduced 
nuclear levels of DNA-PK. We have shown that DNA-PK 
promotes the HIV transcriptional initiation by catalyzing 
the phosphorylation of RNAP II CTD at Ser5; it relieves 
the pausing of RNAP II by catalyzing the phosphorylation 
of TRIM28 at S824. Finally, DNA-PK increases the 
elongation phase of HIV transcription by augmenting CTD 
phosphorylation at Ser2, both by directly catalyzing the 
reaction and by co-recruiting P-TEFb at HIV LTR.
RESULTS
DNA-PK inhibitors are strong repressors of HIV 
transcription, replication, and reactivation of 
latent HIV provirus
We have shown previously that DNA-PK plays a 
significant role during HIV transcription [16]. To extend 
those findings and in our quest to define the molecular 
mechanisms involved, we evaluated the role of DNA-
PK in supporting proviral reactivation from latency. Our 
hypothesis was that DNA-PK inhibition should impair 
HIV transcription, and consequently latent proviral 
reactivation. For testing this hypothesis, we assessed the 
reactivation of proviruses in latently infected cell lines and 
primary T cells in the presence of highly specific and well-
established DNA-PK inhibitors. Using our established 
methodologies, we generated the latently infected THP-
1, a human myeloid/monocytic cell line, Jurkat, a human 
lymphoid/T cell line, and primary CD4+ T cells [8, 60]. 
Using luciferase assays, we evaluated the impact of DNA-
PK inhibitors on the reactivation of integrated latent HIV 
provirus (pHR’P-Luc) expressing luciferase reporter 
gene under the control of the HIV LTR promoter (Figure 
1A). The cells were incubated overnight with various 
concentrations of different DNA-PK inhibitors or DMSO, 
as solvent control. The cells were stimulated with either 
Tumor Necrosis Factor alpha (TNF-α) or T cell receptor 
(TCR). A clear dose-dependent inhibition of HIV proviral 
reactivation by DNA-PK inhibitors was observed in all 
cell types, indicated by the reduced luciferase counts in 
cells treated with the inhibitors compared to the control 
(Figure 1B–1D). The more specific DNA-PK inhibitors, 
NU7441 and NU7026, demonstrated better effect in 
restricting HIV gene expression than the less specific 
inhibitor IC86621. Since IC86621 was comparatively less 
efficient in restricting HIV transcription, in successive 
experiments we primarily used NU7441 and NU7026.
In order to exclude the possibility that the loss of 
luciferase activity was due to non-specific cell cytotoxicity 
of DNA-PK inhibitors, we treated the cells with NU7441 
and NU7026 and then assessed cell viability using 
the MTS assay. We did not find any significant cell 
cytotoxicity in Jurkat and THP-1 cells up to 64 µM even 
after 5 days of culture (Figure 1E and 1F). However, in 
case of primary CD4+ T cells, DNA-PK inhibitors showed 
some toxicity at concentrations around 32 µM (Figure 1G). 
Therefore, in our successive analyses involving primary T 
cells, we used concentrations of inhibitors below 32 µM.
Taken together, our data suggest that DNA-PK 
inhibitors efficiently restrict proviral reactivation from 
latency by down-regulating HIV gene expression. The 
stronger suppression of HIV gene expression by the more 
specific DNA-PK inhibitors indicates target-specific 
inhibition and confirms the vital role of DNA-PK during 
HIV transcription.
We further used U1 (Figure 2A) and J1.1 (Figure 
2B) cells to investigate the effect of DNA-PK inhibitors 
on latent proviral reactivation and HIV replication. The 
U1 is a latently infected monocytic cell line, while the 
J1.1 is a latently infected Jurkat T cell line; both carry 
an integrated replication-competent latent HIV provirus. 
The cells were treated with different amounts of DNA-
PK inhibitors or DMSO control, overnight (~11 hours). 
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Figure 1: DNA-PK inhibitors repress HIV transcription without showing cytotoxicity. (A) HIV- based lentiviral vector, 
pHR’P-Luc, which express luciferase reporter gene through HIV LTR promoter. (B) THP-1, a monocytic cell line, (C) Jurkat, a T cell line, 
and (D) primary CD4+ T cells carrying integrated latent pHR’P-Luc provirus in their genome were treated with indicated amounts of the 
DNA-PK inhibitors NU7441, NU7026, IC86621 or DMSO solvent-control along with or without 10 ng/ml of TNF-α. After 48 hours cells 
were lysed, and equal amount of proteins were used for luciferase assays. MTS cell viability assays were also performed after 5 days of 
culture (E) THP-1-pHR’P-Luc, (F) Jurkat-pHR’P-Luc and (G) primary CD4+ T cells-pHR’P-Luc. The results represent the Mean ± SD of 
three independent assays. The p value of statistical significance was set at either: p < 0.05 (*), 0.01 (**), 0.001 (***), or 0.0001 (****) when 
compared with DMSO treated stimulation as control.
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Figure 2: DNA-PK inhibitors drastically impair latent proviral reactivation and HIV replication. For assessing the impact 
of DNA-PK inhibitors on the latent proviral reactivation and replication, the cells were pre-incubated with indicated amounts of DNA-
PK inhibitors or DMSO control, overnight. Next day, cells were supplied with fresh media containing inhibitors and/or 10 ng/ml TNF-α, 
accordingly, and further incubated for 48 hours. The cell supernatants were collected and used for the Reverse Transcriptase (RT) assays 
performed in (A) U1 (latently infected U937 based monocytic cell line), (B) J1.1 cell line (latently infected Jurkat based T cell line) and (C) 
Freshly infected primary CD4+ T cells. The results represent the mean ± SD of three independent assays. The statistical significance was set 
at: p < 0.05 (*), 0.01 (**), 0.001 (***), or 0.0001 (****) versus DMSO treated stimulated cells, as control.
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Next day, cells were supplied with fresh media containing 
inhibitors and/or 10 ng/ml TNF-α for another 48 hours, 
and the activity of HIV reverse transcriptase (RT) was 
analyzed in cell supernatants. We noticed a steady 
suppression of HIV replication by DNA-PK inhibitors in 
a dose-dependent manner (Figure 2A and 2B). Similar to 
the results obtained in the transcription assays, the more 
specific inhibitors NU7441 and NU7026 were more 
effective than IC86621 in restricting HIV replication in 
both cell types. Comparable results from both J1.1 and U1 
cells confirmed the vital role of DNA-PK in facilitating 
HIV gene expression and replication irrespective of cell 
lineage. These data also suggest the therapeutic potential 
of DNA-PK inhibitors in restricting the reactivation of 
latent HIV proviruses and subsequent replication.
To provide physiological relevance to the anti-HIV 
effect of DNA-PK inhibitors, we examined the impact of 
DNA-PK inhibitors on HIV replication in primary CD4+ T 
cells isolated from human peripheral blood mononuclear 
cells (PBMCs) (Figure 2C). CD4+ T cells were activated 
with PHA and IL-2, infected with a CXCR4 tropic HIV 
virus (NL4-3), and treated with different concentrations 
of the most effective DNA-PK inhibitor, NU7441. 
The culture medium containing NU7441 was replaced 
every 3 days. The results of the RT assays performed 
at 5, 7, and 9 days post-infection showed that NU7441 
effectively repressed HIV replication in primary CD4+ 
T cells in a dose-dependent fashion. Taken together, our 
results confirm the pivotal role of DNA-PK during HIV 
transcription, latent proviral reactivation and replication.
DNA-PK promotes HIV transcription by 
enhancing the phosphorylation of C-terminal 
domain (CTD) of RNA polymerase II (RNAP II)
In our prior publication, by performing in vitro 
kinase assays, we have shown the phosphorylation of 
RNAP II CTD by DNA-PK, a crucial post-translational 
modification, is required to generate complete functional 
transcripts, as it makes RNAP II processive [16]. In 
order to understand whether the observed inhibition of 
the HIV gene expression by DNA-PK inhibitors is the 
result of insufficient phosphorylation of RNAP II CTD, 
we assessed the impact of DNA-PK inhibitors on RNAP 
II CTD phosphorylation. Jurkat (Figure 3A) and U937 
(Figure 3C) were treated with the DNA-PK inhibitor 
NU7441 at different concentrations for 3 hours. The 
nuclear extracts were run on an acrylamide gel, transferred 
to a nitrocellulose membrane, and the membrane was 
developed using antibodies that recognize specific epitopes 
present on the CTD of phosphorylated RNAP II. The H5 
antibody recognizes the RNAP II with CTDs carrying 
Ser2 phosphorylation, while the H14 antibody recognizes 
epitopes of CTD carrying Ser5 phosphorylation. A dose-
dependent effect of NU7441 on the phosphorylation of 
Ser2 and Ser5 of RNAP II CTD in both Jurkat (Figure 
3A and 3B) and U937 cells (Figure 3C and 3D) was 
observed significantly (Figure 3). However, total RNAP II 
levels were not much affected. These results were further 
validated in different cell lines: THP-1 (a myeloid cell 
line); MT-4 (a T cell line harboring HTLV in its genome); 
2D10 (a Jurkat cell line carrying latent HIV in its genome) 
[8, 61]; and primary cells (Supplementary Figures 1–4). 
The parallel impairment of HIV gene expression (Figures 
1 and 2) and CTD phosphorylation (Figure 3), upon DNA-
PK inhibition, suggests an important role for DNA-PK-
mediated CTD phosphorylation in generating processive 
RNAP II, a requirement for efficient gene expression. 
In addition, the present study validates our prior in vitro 
findings and confirms that RNAP II CTD is indeed the 
physiologic substrate for DNA-PK. The impact of DNA-
PK inhibitors on both types of CTD phosphorylation 
modifications indicates that DNA-PK plays a role in 
both the initiation and elongation phases of transcription. 
Notably, the reduction in Ser5 phosphorylation is less 
pronounced than the reduction in Ser2 phosphorylation 
following inhibition of DNA-PK, indicating that DNA-PK 
facilitates HIV transcription predominantly by supporting 
the elongation phase.
Overall, these results confirm that DNA-PK 
catalyzes the phosphorylation of RNAP II CTD and 
suggest that the observed reduction in HIV transcription 
and replication following treatment with DNA-PK 
inhibitors is a direct consequence of reduced CTD 
phosphorylation of RNAP II.
Knockdown of endogenous DNA-PK restricts 
RNAP II CTD phosphorylation
In order to confirm that the effects we observed 
after DNA-PK inhibition were due to the impairment 
of DNA-PK activity, we performed a knockdown of 
endogenous DNA-PK. To knockdown endogenous DNA-
PK, the U937 and Jurkat cells were infected with lentiviral 
vectors expressing shRNAs either against the catalytic 
subunit of DNA-PK (DNA-PKc) or scrambled shRNA, as 
control. The neutrality of scrambled shRNA towards HIV 
and cellular genomes was confirmed by using the NCBI 
program Blast [8]. Depending on the degree of DNA-PK 
knockdown in different clones, we selected one clone each 
for U937 (clone U3) (Figure 4A and 4B) and Jurkat (clone 
J3) (Figure 4C and 4D) for further analysis. In the case 
of the U937 clone U3, we were able to obtain more than 
85% knockdown (Figure 4A), whereas in the case of the 
Jurkat clone J3, the knockdown was 70% (Figure 4C). 
We also noted profound cell death in Jurkat cells, with 
over 70% depletion of endogenous DNA-PK. In both 
knockdown clones, we noted significant loss of the CTD 
phosphorylation, at both Ser2 and Ser5 (Figure 4). We also 
observed some reduction of the total RNAP II levels in 
U937 cells, likely due to high level of DNA-PK depletion. 
Given the fact that RNAP II is also required for RNAP 
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Figure 3: DNA-PK inhibitors repress HIV transcription by restricting RNAP II CTD phosphorylation. (A) Jurkat cells 
and (C) U937 cells were treated with increasing concentrations of the DNA-PK inhibitor NU7441 and then activated with TNF-α (10 ng/
ml) for 3 hours. The cells were harvested, and nuclear extracts were assessed through western blot. The phosphorylation state of carboxyl 
terminal domain (CTD) of RNA polymerase II (RNAP II) was assessed through western blot using antibodies that are specific for RNAP II 
and its phosphorylated forms (Ser2 and Ser5). HDAC1 was used as loading control. The presented data is one representative western blot 
analysis out of three. Densitometric analyses were performed on western blot bands using ImageJ software for both (B) Jurkat cells and (D) 
U937 cells. The results represent the Mean ± SD of three different independent assays. Statistical significance is set as p < 0.05 (*), 0.01 (**), 
or 0.001 (***) compared to stimulated, but without DNA-PK inhibitor.
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Figure 4: Knockdown of DNA-PK restricts RNAP II CTD phosphorylation. The endogenous DNA-PK was knocked down 
using lentiviral vectors expressing shRNA sequences specific for DNA-PK. The vector expressing non-targeting scrambled shRNA 
sequence was used as control. Western blot assays showing nuclear levels of DNA-PK, total RNAP II, RNAP II (Ser2) and RNAP II (Ser5) 
in (A) U937 cells and corresponding DNA-PK knockdown clone U3 and (C) Jurkat cells and DNA-PK knockdown clone J3. β-Actin and 
HDAC1 were used as loading controls. Densitometric analyses were performed on (B) U937 cells and (D) Jurkat cells western blot’s bands 
using imageJ software. Error bars represent the SD of three separate experiments. Statistical significance was set as p < 0.05 (*), 0.01 (**), 
0.001 (***) or 0.0001 (****) versus scrambled shRNA control.
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II gene expression, severe defects to the functionality of 
cellular RNAP II hamper its own expression, an effect also 
observed upon using strong inhibitors of P-TEFb (data not 
shown). These results, along with those obtained using 
DNA-PK inhibitors (Figure 3), confirm that DNA-PK 
catalyzes RNAP II CTD phosphorylation, which promotes 
HIV transcription.
DNA-PK promotes HIV transcription by 
supporting the recruitment of P-TEFb at HIV LTR
The interaction between DNA-PK and P-TEFb 
has been previously documented [62, 63]. CDK9 
subunit of P-TEFb is the major kinase that catalyzes 
the phosphorylation of RNAP II CTD. This observation 
suggests that in addition to directly catalyzing the 
phosphorylation of CTD of RNAP II, DNA-PK may 
also enhance CTD phosphorylation by increasing the 
recruitment of P-TEFb at HIV LTR. Therefore, we 
examined the recruitment profile of the main subunits of 
P-TEFb, Cyclin T1, and CDK9, at HIV LTR by performing 
chromatin immunoprecipitation (ChIP) assays in wild-
type and DNA-PK knockdown cells. Given that T cells 
are the main reservoirs of latent proviruses, we performed 
experiments using Jurkat T cells. The recruitment kinetics 
of P-TEFb were analyzed in knockdown (J3) and control 
Jurkat clones harboring latent HIV provirus, pHR’-PNL-
wildTat-d2GFP (Jurkat-HIV-GFP) (Figure 5A), before and 
after activation with TNF-α (10 ng/ml) for 30 minutes.
The ChIP assays were performed using antibodies 
against Cyclin T1 and CDK9. We also analyzed CDK7, 
a component of the TFIIH transcription factor, which 
catalyzes the phosphorylation of RNAP II CTD primarily 
at Ser5 residue, hence playing vital role during the 
initiation phase of HIV transcription [35]. As control, 
we assessed the recruitment of RNAP II, a marker of 
ongoing transcription, and an auto-phosphorylated form 
of DNA-PK, specifically at S2056, p-DNA-PK (S2056), 
which marks the functionally active form of DNA-PK. 
The immunoprecipitated DNA was examined by using 
two primer sets: one amplifying the promoter region of 
the LTR (–116 to +4 with respect to the transcription 
start site), which provides a measure of the factors 
involved in transcriptional initiation (Figure 5B), and 
the other amplifying the downstream nucleosome-2 
region (Nuc-2) of the LTR (+286 to +390 with respect to 
the transcription start site), which quantifies the factors 
involved in the elongation phase of HIV transcription 
(Figure 5C). The IgG control was subtracted from all 
samples as background. The results were normalized 
with the housekeeping GAPDH gene (–145 to +21), a 
constitutively expressing cellular gene. In Figure 5B, 
the low level of RNAP II at the promoter region of 
latent provirus marks reduced ongoing transcription. 
Interestingly, we also noted highly reduced presence 
of p-DNA-PK (S2056), suggesting that due to reduced 
level of DNA-PK in latently infected cells, HIV provirus 
was unable to initiate its transcription. However, upon 
induction with TNF-α, the latent provirus gets reactivated, 
as indicated by the rapid, more than 3-fold enrichment 
of RNAP II at the promoter. Parallel to the RNAP II 
accumulation, we found enhanced recruitment of DNA-
PK at the promoter, validating the pivotal role of DNA-
PK in HIV transcription. The enhanced nuclear-levels of 
DNA-PK upon cell stimulation were also validated in 
other experiments (Figures 3 and 8). As anticipated, we 
noted relatively less recruitment of P-TEFb subunits at 
the promoter region. However, at a distal Nuc-2 region 
of LTR, we noticed significantly higher enrichment of 
P-TEFb upon activation, validating the main role of 
P-TEFb during the elongation phase of transcription. 
On the other hand, after activation, CDK7 was enriched 
as expected at the LTR promoter but not at the Nuc-2 
region, again validating its requirement especially during 
the initiation phase of HIV transcription. As shown in our 
previous publication [16], we noted better enrichment 
of DNA-PK at the downstream Nuc-2 region of LTR 
after activation, validating the main role of DNA-PK 
during transcriptional elongation. However, in DNA-PK 
deficient cells, we observed highly reduced recruitment 
of almost all of the factors, further validating the highly 
restricted ongoing HIV transcription. Interestingly, even 
after stimulation with TNF-α, we found highly impaired 
enrichment of P-TEFb at LTR, confirming a clear role of 
DNA-PK in P-TEFb recruitment. Notably, we observed 
a relatively smaller impact of DNA-PK knockdown on 
CDK7 recruitment at the promoter region, suggesting 
that CDK7 recruitment at LTR does not depend on the 
DNA-PK.
Together, our results demonstrated that DNA-
PK promotes HIV transcription, not only by directly 
catalyzing the phosphorylation of CTD of RNAP II [16], 
but also by enhancing the recruitment of P-TEFb at HIV 
LTR, which further increases CTD phosphorylation.
DNA-PK depletion in cells severely impairs HIV 
gene expression
To confirm the direct involvement of DNA-PK 
in promoting HIV transcription, we assessed the effect 
of DNA-PK knockdown on HIV gene expression. We 
superinfected DNA-PK knockdown cells or control cells 
that carry scrambled shRNA, with pHR’-PNL-H13LTat-
d2GFP or pHR’-PNL-wildTat-d2GFP. These non-
replicating HIV have similar backbones, and both express 
the GFP reporter gene under the control of the HIV LTR 
promoter (Figure 5A). The only difference between them 
is that one expresses wild-type Tat and the other mutated 
Tat (H13L), a partially defective Tat mutant highly 
prevalent in latent proviruses [8, 61, 64]. Interestingly, 
for both Jurkat and U937 cells, upon superinfection with 
pHR’-PNL-H13LTat-d2GFP in DNA-PK depleted cells, 
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Figure 5: DNA-PK facilitates the recruitment of P-TEFb at HIV LTR. (A) Schematic diagram of HIV based lentiviral vector, 
which carry either mutated Tat (H13L) or wild-type Tat and express GFP as reporter. In these experiments VSV-G pseudotyped HIV, 
harboring wild-type Tat gene (HIV-GFP), was used. The DNA-PK knockdown (J3) or control Jurkat cells with scrambled shRNA were 
infected with HIV-GFP and the provirus was allowed to become latent. The ChIP assays were performed before and after reactivating 
the latent provirus with TNF-α (10 ng/ml) for 30 minutes. ChIP assays were done using indicated antibodies and two transcriptionally 
relevant regions of LTR were amplified using specific primer sets: (B) promoter region of the LTR; and (C) Nuc-2 region  of the LTR. HIV 
DNA levels were calculated as percentages of the reaction input after background subtraction. Error bars represent the mean ± SD of four 
independent experiments and three separate real-time qPCR measurements. Statistical significance, p < 0.05 (*), 0.01 (**), or 0.001 (***), 
indicates enrichment at LTR following latent proviral reactivation, in both wild and DNA-PK knockdown conditions.
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we noted more than 4-fold reduction of GFP positive cells 
in comparison to control cells carrying scrambled shRNA 
(Figure 6A and 6B). However, in cells infected with 
HIV expressing wild-type Tat gene, pHR’-PNL-wildTat-
d2GFP, we observed relatively less impaired HIV gene 
expression, but still more than 2-fold reduction of GFP 
positive cells in DNA-PK depleted cells. Given the fact 
that the expression of GFP gene is controlled by the HIV 
LTR promoter in these HIV constructs, the GFP expression 
marks HIV gene expression and LTR activation. These 
results demonstrate that DNA-PK plays a crucial role in 
promoting HIV gene expression. Accordingly, similar 
to GFP expression, we noticed reduced levels of Tat in 
DNA-PK knockdown U2 and U3 clones infected with 
pHR’-PNL-wildTat-d2GFP (Figure 6C), suggesting that 
a DNA-PK-mediated transcriptional boost is essential for 
generating optimal Tat levels as well.
The results were also confirmed at the mRNA 
level. The cellular RNAs were extracted from control and 
DNA-PK knockdown cell clones infected with pHR’-
PNL-wildTat-d2GFP; cDNAs were synthesized and equal 
amounts of cDNAs were quantified via real-time PCR 
analysis (qPCR) using primer set for the downstream 
Nuc-2 region of HIV LTR. Analogously to GFP levels, 
we observed a significantly reduced expression of HIV 
mRNA in DNA-PK knockdown clones compared to cells 
that express normal levels of DNA-PK (Figure 6D and 
6E). These data confirm that GFP expression is impaired 
at transcriptional level in DNA-PK deficient cells.
DNA-PK enhances HIV transcription by 
facilitating the recruitment of transcriptional 
machinery and generating transcriptionally 
active euchromatin structures at HIV LTR
It is well-established that the type of chromatin 
structure and the transcription factors present at the gene 
promoter and nearby regions regulate its transcription [60, 
65]. We examined the recruitment of the main transcription 
factors and induced chromatin structures at and around the 
HIV LTR promoter. Heterochromatin or closed chromatin 
structures repress transcription, whereas, euchromatin 
or open chromatin structures facilitate transcription by 
allowing access to the transcription machinery at the 
promoter [3, 5, 7]. Hence, to characterize the underlying 
molecular mechanisms through which DNA-PK promotes 
HIV gene expression and replication, we evaluated the 
changes to chromatin structures at HIV LTR before and 
after inhibiting DNA-PK.
To examine whether DNA-PK inhibitors instigate the 
generation of transcriptionally repressive heterochromatin 
structures at HIV LTR, ChIP assays were performed. The 
most specific inhibitor of DNA-PK, NU7441 (12 µM), was 
used to assess the impact of DNA-PK inhibition in Jurkat-
pHR’P-Luc cell line. ChIP assays were performed before 
and after activating the latent provirus with TNF-α in the 
absence or presence of the DNA-PK inhibitor (Figure 7A 
and 7B). The immunoprecipitated DNA was analyzed 
using two different primer sets. One primer set amplified 
the promoter region of the LTR (–116 to +4 with respect 
to the transcription start site) (Figure 7A) and the other 
the nucleosome-1 (Nuc-1) region of the LTR (+30 to 
+134 with respect to the transcription start site) (Figure 
7B), an adjacent critical region, where slight epigenetic 
changes affect overall HIV gene expression [66, 67]. The 
data obtained through immunoprecipitation using control 
IgG was subtracted from all samples as background and 
results were normalized with housekeeping GAPDH gene 
expression (–145 to +21) level. At both promoter and Nuc-1 
regions, the latent proviruses had low levels of associated 
RNAP II (Figure 7), which increased by several folds 
following TNF-α treatment. However, in the presence of 
the DNA-PK inhibitor, TNF-α stimulation was significantly 
weak. The limited amount of RNAP II at HIV LTR in the 
presence of DNA-PK inhibitors is an indication of impaired 
HIV transcription. In parallel, we noted reduced recruitment 
of DNA-PK and P-TEFb (cyclinT1) in NU7441 treated 
cells (Figure 7A and 7B). Additionally, since pHR’P-Luc 
does not carry Tat gene, our data validate that Tat is not 
required for DNA-PK recruitment at LTR.
TNF-α activates (nuclear translocation) NF-κB, 
and the greater recruitment of p65, a main subunit of 
NF-κB, marks the enhanced NF-κB binding at LTR after 
activation. Consistent with the fact that NF-κB binding 
sites reside in the promoter area of LTR, we found higher 
recruitment of p65 in the promoter area after stimulation 
with TNF-α (Figure 7A). Notably, we also observed 
some recruitment of p65 in the neighboring Nuc-1 region 
after stimulation with TNF-α. Given the ChIP resolution 
limit of ~500 bp, an overlap of signals between adjacent 
regions, such as promoter and Nuc-1, was expected. 
After binding to the promoter, NF-κB is known to recruit 
histone acetyltransferases (HATs) at HIV LTR, which 
in turn acetylate the core histones [68]. The augmented 
levels of acetylated histone H3 (H3-Ac), especially in 
the Nuc-1 region, marks the presence of higher levels of 
acetylated core histones at HIV LTR. We also observed 
the concomitant loss of histone deacetylases, HDACs, 
(HDAC3) from LTR further suggests that not only 
the recruitment of HATs, but dissociation of HDACs 
from LTR is responsible for establishing euchromatin 
structures at LTR. Following the treatment with NU7441, 
the euchromatic marker H3-Ac went down; instead, the 
heterochromatic marker H3K27me3 got established at 
HIV LTR (Figure 7). These heterochromatic markers 
indicate the presence of transcriptionally repressive 
heterochromatin structure at HIV LTR, resulting in 
reduced levels of RNAP II and DNA-PK at LTR, which 
eventually translate to reduced HIV transcription, gene 
expression, and replication.
Consequently, it can be deduced from these 
results that DNA-PK enhances HIV gene expression by 
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Figure 6: DNA-PK plays a vital role in HIV gene expression. Flow cytometric analyses of freshly infected DNA-PK knockdown 
or control cells with either pHR’-PNL-H13LTat-d2GFP or pHR’-PNL-wildTat-d2GFP. (A) DNA-PK knockdown Jurkat clone J3 and 
control Jurkat with scrambled shRNA. (B) DNA-PK knockdown U937 cell clones, U2 and U3, and control cells with scrambled shRNA. 
After 48 hours post-infection, GFP positive cells were analyzed using a flow cytometer. The uninfected Jurkat and U937 were used as 
background control. (C) Tat protein levels in DNA-PK knockdown U2 and U3 clones infected with pHR’-PNL-wildTat-d2GFP analyzed 
via western blot. (D and E), the relative expression levels of HIV mRNA in DNA-PK knockdown and scrambled control cells were 
evaluated via RT-qPCR. The qPCR results represent the mean ± SD of three independent assays. Statistical significance, p < 0.001 (***), 
marks restriction to HIV gene expression, following DNA-PK knock down.
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Figure 7: DNA-PK facilitates both the recruitment of transcription factors and establishment of euchromatin structures 
at HIV LTR. ChIP analysis in Jurkat-pHR’P-Luc before and after activating latent HIV provirus with TNF-α in the absence or presence of 
DNA-PK inhibitor NU7441. The cellular chromatin was immunoprecipitated using indicated antibodies. The recovered DNA was analyzed 
using primer sets amplifying (A) the promoter region of the LTR, and (B) nucleosome-1 (Nuc-1) region of the LTR. Data is represented 
as percentages of the input nuclear extract after background subtraction. Results represent the mean ± SD of two independent experiments 
and three separate real-time qPCR measurements. Statistical analysis signifies the recruitment kinetics following reactivation of the latent 
provirus in the presence of NU7441 at HIV LTR; p < 0.05 (*).
Oncotarget712www.oncotarget.com
facilitating the establishment of transcriptionally active 
chromatin structures at HIV LTR. DNA-PK inhibitors 
restrict HIV transcription by reversing those changes and 
inducing the establishment of transcriptionally repressive 
heterochromatin structures at LTR.
DNA-PK facilitates RNAP II pause release by 
phosphorylating and recruiting TRIM28 at LTR
DNA-PK has been shown to interact and catalyze the 
TRIM28 phosphorylation at serine 824 residue, p-TRIM28-
(S824) [37, 39]. This modification converts TRIM28 from 
a transcriptionally repressive factor to a transcriptionally 
active factor [37–39]. It has been recently documented 
that TRIM28 potently suppresses HIV-1 expression by 
utilizing both SUMO E3 ligase activity and epigenetic 
adaptor function [43]. We hypothesized that if DNA-PK 
plays a major role in TRIM28 activation by catalyzing its 
phosphorylation at serine 824, then DNA-PK inhibition or 
depletion in cells should reduce TRIM28 phosphorylation 
and thus contribute to the suppression of HIV gene 
repression, observed upon ablation of DNA-PK. We 
examined the effect of DNA-PK inhibitors on the TRIM28 
phosphorylation at the serine 824 residue by western blot, 
using an antibody that detects specifically p-TRIM28-
(S824). Jurkat cells were treated overnight with the DNA-
PK inhibitor NU7441; then cell media was replaced with 
fresh media containing NU7441 along with TNF-α. After 
30 minutes, nuclear-extracts were prepared and the levels of 
TRIM28 and p-TRIM28-(S824) were assessed. The results 
showed that DNA-PK inhibitor effectively reduced TNF-α-
induced TRIM28-(S824) phosphorylation (Figure 8A and 
8B). However, the total TRIM28 protein levels were almost 
unaffected upon DNA-PK inhibition.
We further evaluated the impact of DNA-PK 
knockdown on TRIM28 and p-TRIM28-(S824) in J3 
clone of Jurkat cells. Following DNA-PK depletion, we 
observed clear reduction in p-TRIM28-(S824) levels 
(Figure 8C and 8D). Interestingly, we also noted some 
reduction in the total TRIM28 levels. Overall data suggest 
that DNA-PK-mediated activation (phosphorylation) 
of TRIM28 may contribute to DNA-PK induced HIV 
transcription by relieving paused RNAP II. To confirm this 
notion, we next analyzed the recruitment of TRIM28 and 
p-TRIM28-(S824) in the presence and absence (depletion) 
of DNA-PK at HIV LTR. This analysis used the DNA-PK 
knocked-down clone J3 and control (scrambled shRNA) 
Jurkat cells carrying the latent HIV provirus, pHR’-PNL-
wildTat-d2GFP (Jurkat-HIV-GFP), in their genome. The 
ChIP assays were performed before and after activating 
the cells with TNF-α (10 ng/ml) for 30 minutes. The 
immunoprecipitated DNA was analyzed using two primer 
sets, one amplifying the promoter region of the LTR (–116 
to +4 with respect to the transcription start site, Figure 
9A) and another downstream Nuc-2 region of the LTR 
(+286 to +390 with respect to the transcription start site, 
Figure 9B). In case of wild-type cells with scrambled 
shRNA, upon TNF-α treatment the latent provirus got 
reactivated, indicated by the higher recruitment of RNAP 
II. Interestingly, in parallel to the recruitment profile 
of DNA-PK after activation, we observed enhanced 
recruitment of TRIM28 at both the promoter and Nuc-2 
regions. However, we noticed relatively more enrichment 
of p-TRIM28-(S824) at the Nuc-2 region after activation. 
In case of DNA-PK knockdown cells, we noticed impaired 
recruitment of TRIM28 and p-TRIM28-(S824) at HIV 
LTR. However, upon stimulation with TNF-α, we found 
some, but still highly restricted recruitment of TRIM28 
and p-TRIM28-(S824). The decrease in the recruitment 
of TRIM28 and p-TRIM28-(S824) at HIV LTR following 
DNA-PK depletion, clearly suggests a contribution of 
DNA-PK in TRIM28 recruitment at HIV LTR. Moreover, 
restricted RNAP II levels at both promoter and Nuc-
2 region of provirus in DNA-PK knockdown cells, 
further validates the highly reduced ongoing HIV gene 
expression, which again validates the importance of DNA-
PK during the reactivation of latent HIV provirus. These 
findings reveal yet another way through which DNA-PK 
contributes to HIV transcription.
DNA-PK inhibitors severely impair HIV-1 
replication and transmission in MT-4 cells
The human T cell line MT-4 carrying Human T cell 
Lymphotropic Virus-1 (HTLV-1) is highly susceptible 
to HIV-1 infection and induced toxicity. We used these 
cells to examine the ability of NU7026 and NU7441 
inhibitors to suppress spreading of HIV-1 infection and 
evaluate the cytotoxicity of these compounds. The cells 
were pre-treated for 24 hours with various concentrations 
of the two compounds (2, 4, 8, 16, 32 µM) or the highest 
concentration of DMSO used to dilute the compounds as 
control. The next day the cells were infected with ×4LAI.04, 
washed two times in PBS and plated in 24-well plates 
(for HIV infection) and 96-well plates (for MTT assay) 
in medium containing the compounds. After 3 days, the 
concentration of p24 was evaluated in the medium and 
MTT assay was performed.
As shown in Figure 10A and 10B, both DNA-PK 
inhibitors strongly inhibit HIV-1 replication compared 
to the DMSO control. Moreover, NU7441, being a 
highly specific inhibitor, inhibits HIV gene expression 
more effectively at lower doses (Supplementary Figure 
4C). The compounds were not cytotoxic even at highest 
concentrations (Figure 10C and 10D).
DNA-PK inhibitor restricts the reactivation 
of latent proviruses in peripheral blood 
mononuclear cells (PBMCs) from HIV patients
Overall, the results documented so far confirm an 
important role of DNA-PK in supporting HIV transcription 
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and replication. We have shown that the small molecule 
inhibitors of DNA-PK efficiently restrict HIV gene 
expression, replication, and the reactivation of latent 
proviruses in different cell types. To provide the clinical 
relevance to these findings, we evaluated the ability of 
DNA-PK inhibitors to restrict the reactivation of latent 
HIV proviruses present in the PBMCs of HIV patients 
on combination anti-retroviral treatment (cART). Ten 
Figure 8: DNA-PK catalyzes the phosphorylation of TRIM28. Western blots were performed to evaluate the expression levels 
of Trim28 and phospho-Trim28 [p-TRIM28 (S824)] in (A) Jurkat cells treated with increasing concentration of the DNA-PK inhibitor 
NU7441 with or without TNF-α, and in (C) DNA-PK knockdown clone J3 and scrambled shRNA control. Densitometric analyses of 
(B) Jurkat cells and (D) DNA-PK knockdown J3 clone were performed using ImageJ software. Data is expressed as mean ± SD; n = 3. 
Significant differences in protein expression were evaluated; p < 0.05 (*), 0.01 (**), or 0.001 (***) against the respective controls.
Oncotarget714www.oncotarget.com
million PBMCs from 4 HIV-infected patients undergoing 
successful cART treatment (undetectable viral load) were 
mixed and used in each sample. The cells were treated 
with either cART (2 NRTIs+1 PI, Zidovudine/Abacavir/
Fosamprenavir) alone, with DNA-PK inhibitor, NU7441 
(12 µM) alone, or together with both NU7441+cART, 
Figure 9: DNA-PK facilitates TRIM28 recruitment at HIV LTR. Recruitment kinetics of TRIM28 and p-TRIM28-(S824) 
were assessed using ChIP assays in J3 and scrambled control, and also before and after reactivating latent HIV provirus. (A) Primer 
set amplifying the promoter region of the LTR and (B) primers amplifying the downstream Nuc-2region of the LTR. Data represent the 
percentages of the input after background subtraction. Results depicts the mean ± SD of two independent experiments and three separate 
real-time qPCR measurements. Statistical significance, p < 0.05 (*) or 0.01 (**), marks the reactivation of latent HIV provirus in both wild 
or reduced DNA-PK conditions.
Oncotarget715www.oncotarget.com
overnight. The next day, culture medium was replaced 
with fresh medium containing cART and/or NU7441, and 
the cells were stimulated with PMA/ionomycin/IL-2 for 
3 days to reactivate latent HIV provirus. Cellular RNA 
was isolated, cDNA was prepared and equal amounts of 
cDNA (5 ng) were analyzed by qPCR, with a primer set 
specific for the Nuc-2 region of LTR. The results were 
normalized with GAPDH gene amplification as loading 
control. We found that NU7441, with or without cART, 
was able to restrict the reactivation of latent provirus, 
which occurs following the stimulation with PMA/
ionomycin/IL-2. Notably, cART alone was not effective 
in controlling latent proviral reactivation and HIV gene 
expression (Figure 11A). Notably, NU7441 also restricted 
the reactivation of latent provirus which was partially 
reactivated while thawing the PBMCs (compare lanes 1 
to 3 and 5). Viability of PBMCs was not compromised 
by the treatments (Figure 11B). Instead, drug treatments, 
by virtue of repressing HIV replication, enhanced 
cell survival. This result validates our hypothesis that 
transcriptional inhibitors, such as DNA-PK inhibitors, can 
be used to suppress the ectopic reactivation of latent HIV 
Figure 10: DNA-PK inhibitors completely block HIV replication in MT-4 T cells without showing cytotoxicity. MT-4 cells 
were treated overnight with increasing concentrations of the DNA-PK inhibitors (A) NU7026 or (B) NU7441; DMSO was used as solvent 
control. Next day, the cells were infected with a replication competent ×4 virus (HIVLAI.04). After 3 days of culture, cells supernatants were 
evaluated for p24 with Luminex (Luminexcorp). Significant inhibition of HIV replication in presence of DNA-PK inhibitors (increasing 
dose) were evaluated; p < 0.0001 (****). The cytotoxicity of the inhibitors in MT-4 cells was assessed with MTT assay. No cytotoxicity was 
detected in cells treated with (C) NU7026 or (D) NU7441, compared to the DMSO control. All the results represent the mean ± SD of four 
independent measurements.
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provirus, a main contributor to viral blips, even in HIV 
patients undergoing successful cART.
DNA-PK promotes HIV transcription by 
supporting different aspects of HIV transcription
In order to summarize our results, we present the 
following model (Figure 12). Based on our previous 
[16] and present studies, we propose that DNA-PK 
promotes the initiation phase of HIV transcription mainly 
by directly catalyzing the phosphorylation of RNAP II 
CTD at Ser5. DNA-PK also facilitates the elongation 
phase of transcription by both directly catalyzing the 
phosphorylation of Ser2 of CTD and recruiting P-TEFb 
at LTR. We also found that DNA-PK, by phosphorylating 
TRIM28 at the specific serine residue (S824), converts 
Figure 11: DNA-PK inhibitors restrict the reactivation of latent provirus in PBMCs of HIV-infected patients. PBMCs 
from HIV-infected patients were treated with either ART alone, NU7441 alone or both together overnight. The day after, medium was 
replaced with fresh medium containing the drugs and the cells were stimulated for 3 days with PMA/ionomycin/IL-2 to reactivate latent 
HIV provirus present in PBMCs. (A) Cellular RNAs were isolated and evaluated via RT-qPCR. (B) Cell viability was examined by MTS 
assays. The results were reproduced 3 more times, by mixing PBMCs of 4 different patients each time. Presented data are the mean ± SD 
for four experiments. Statistical significance; p < 0.05 (*) or 0.001 (***) marks the restriction to reactivation of latent provirus in the presence 
of DNA-PK inhibitor.
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it from an RNAP II pausing factor into an elongation-
supporting factor. Thus, DNA-PK also augments HIV 
transcription by relieving the RNAP II pausing. Altogether, 
DNA-PK enhances the HIV transcription by supporting 
the multiple phases of transcription, namely initiation, 
RNAP II pause release, and elongation. Therefore, besides 
controlling replication, DNA-PK inhibition may be used 
to prevent the reactivation of the latent HIV proviruses.
DISCUSSION
Unraveling the molecular mechanisms that control 
HIV life cycle, especially transcription, replication, 
and reactivation of the latent provirus, is crucial for 
cure and eradication of HIV. The studies presented 
herein provide strong and compelling evidence for the 
important role of DNA-PK in supporting various stages 
of HIV transcription, which subsequently promote HIV 
replication and reactivation from latency. We discovered 
that DNA-PK promotes transcriptional initiation by 
catalyzing the phosphorylation of CTD at Ser5; relieves 
RNAP II pausing by phosphorylating TRIM28 at S824; 
facilitates transcriptional elongation by both catalyzing 
the phosphorylation of CTD at Ser2 and promoting of 
P-TEFb recruitment at HIV LTR. Accordingly, we noted 
that DNA-PK inhibition or depletion severely impairs 
HIV transcription, replication, and reactivation of latent 
provirus. Overall, these results reveal the underlying 
molecular mechanisms through which DNA-PK facilitates 
HIV gene expression and reactivation of latent provirus.
The most well-characterized activity of DNA-PK 
is to repair the broken ends of DNA double strand breaks, 
especially during non-homologous end joining (NHEJ) 
DNA-repair pathway [26, 27, 69, 70]. DNA repair, although 
essential for cell survival, may constitute a mechanism of 
tumor resistance to certain DNA damaging agents used 
in cancer treatment, such as radiation exposure [71]. 
Consequently, over-expression of DNA-PKcs is a common 
occurrence in many human cancers [72]. Therefore, 
the inhibition of DNA-PK is an attractive target for the 
development of cancer therapies. Accordingly, DNA-PK 
inhibitors are under trial in several preclinical and phase-I 
clinical studies as anti-cancer agents [45, 56–59]. Although 
very little is known about the cellular consequence of 
DNA-PK, potential utility of DNA-PK inhibitors has been 
proposed as valuable tumor therapeutics.
Notably, DNA-PK was originally discovered as part 
of SP1 transcription complexes [73] and as a regulatory 
Figure 12: DNA-PK facilitates HIV transcription by targeting multiple mechanisms. In our model presented here we suggest 
that DNA-PK supports the initiation phase of transcription by catalyzing the phosphorylation of RNAP II CTD at Ser5. DNA-PK facilitates 
transcriptional elongation by enhancing phosphorylation of RNAP II CTD at Ser2, both via directly catalyzing and through the recruitment 
of P-TEFb at HIV LTR. DNA-PK relieves the RNAP II pausing by catalyzing the phosphorylation of TRIM28.
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component of transcriptionally poised RNA polymerase 
II [74]. However, its role during transcription was studied 
very superficially, and was limited to showing the 
interaction of DNA-PK with RNAP II [16, 21, 44, 75]. 
To extend those observations, for the first time, we have 
shown the importance of DNA-PK during transcription, 
its presence at HIV LTR, and confirmed DNA-PK 
as an integral part of the RNAP II holoenzyme [16]. 
Recently, our findings have been confirmed, and a similar 
mechanism involving DNA-PK has been proposed for the 
transcription of inducible cellular genes [38, 76, 77]. In 
this investigation, we have demonstrated that DNA-PK 
enhances HIV transcription by facilitating the various 
stages of transcription. We also noted reduced nuclear 
level of DNA-PK in unstimulated cells, which upregulates 
upon cell stimulation (Figures 3, 5, and 9), suggesting a 
clear role of reduced DNA-PK levels in supporting HIV 
latency in quiescent cells.
The observation of enhanced recruitment of DNA-
PK at HIV LTR during HIV gene expression and the 
synergistic recruitment kinetics of DNA-PK with RNAP 
II along HIV genome prompted us to explore further the 
role of DNA-PK during HIV transcription, replication, 
and latent proviral reactivation. In this investigation we 
utilized highly specific DNA-PK inhibitors that are known 
to induce phenotypes similar to those seen in DNA-PK 
deficient cell lines and DNA-PK knockout mice [45, 
56]. The knockdown studies reaffirmed the specificity of 
inhibitors towards DNA-PK. Analysis of the reactivation 
of latent HIV provirus expressing luciferase reporter gene 
under the control of HIV LTR promoter unequivocally 
demonstrated that DNA-PK inhibitors are very strong 
repressors of HIV transcription and replication (Figure 
1), since TNF-α, a strong inducer of latent provirus, was 
unable to increase HIV gene expression in the presence 
of optimal concentrations of specific DNA-PK inhibitors. 
The dose-dependent nature of this repression was also 
confirmed in experiments with two different cell lines, 
representing CD4+ lymphoid and myeloid cells, the major 
targets of HIV infection in patients. The physiological 
relevance of these results was established by confirming 
the inhibitory effect of DNA-PK inhibitors in suppressing 
the reactivation of latent HIV provirus in primary CD4+ 
T cells, infected either ex vivo (Figure 1) or obtained from 
HIV patients (Figure 11). We noted some cytotoxicity 
of DNA-PK inhibitors in primary CD4+ T cells at 
concentrations over 16 µM; therefore, the inhibitors 
were always used within physiologically non-toxic range 
(Figure 1). Under these conditions, DNA-PK inhibitors 
even supported the survival of primary cells isolated 
from HIV patients (Figure 11) and also from the MT-4 
cells (Figure 10). This observation confirms that DNA-
PK-mediated inhibition of HIV replication averts HIV-
mediated cytotoxicity.
In our prior study, we have confirmed the presence 
of DNA-PK at HIV LTR and, by performing in vitro 
kinase assays, demonstrated that DNA-PK was able to 
catalyze RNAP II CTD phosphorylation in vitro, using 
purified DNA-PK protein [16]. To extend those in vitro 
findings, here we demonstrated that DNA-PK does, in 
fact, phosphorylate RNAP II CTD in vivo. We have shown 
that following the treatment of cells with either specific 
DNA-PK inhibitor or upon DNA-PK depletion (Figures 
3 and 4), RNAP II CTD phosphorylation (Ser2 and Ser5) 
becomes highly impaired in both Jurkat and THP-1 cells. 
Therefore, our results demonstrate that DNA-PK enhances 
HIV transcription by promoting both the initiation and 
elongation phases of HIV transcription.
The interaction between DNA-PK and P-TEFb 
subunits has also been documented [62, 63]. These 
findings impelled us to determine if DNA-PK also 
increases the RNAP II CTD phosphorylation by bringing 
P-TEFb along with it to HIV LTR. In fact, upon DNA-PK 
depletion, in parallel to impaired DNA-PK recruitment, 
we noted severely decreased recruitment of both P-TEFb 
subunits at HIV LTR (Figure 5). Even after proviral 
reactivation with TNF-α, we observed highly restricted 
recruitment of P-TEFb; we also noted that DNA-PK 
depletion impacted the levels of cellular Tat, the main 
recruiter of P-TEFb at LTR (Figures 5 and 6C).
In DNA-PK knockdown cells, we discovered that 
HIV expressing functionally impaired Tat (H13L), a 
mutation prevalent in latent proviral isolates [8, 61, 64], 
was almost ineffective in supporting HIV transcription. 
Moreover, HIV carrying wild-type Tat was also highly 
defective in expressing the reporter GFP gene (Figure 
6A and 6B). The finding that DNA-PK depletion results 
in reduced HIV protein expression, such as Tat (Figure 
6C), was further supported by the impaired latent proviral 
reactivation and replication in DNA-PK inhibited and 
depleted cells (Figures 1, 2, and 3). Moreover, previously 
we and others have revealed that Tat phosphorylation 
catalyzed by DNA-PK is essential for its optimal 
activity [16, 78]. Hence, besides Tat levels, the deficient 
phosphorylation of Tat due to DNA-PK inhibition 
or depletion may contribute to reduced Tat activity 
and P-TEFb recruitment; this is a subject for future 
investigations.
Given the fact that chromatin structure around the 
promoter of a gene controls its expression, we investigated 
which specific epigenetic changes induced by DNA-PK 
promote HIV transcription, and the reversion of those 
changes upon DNA-PK inhibition (Figure 7). Similar to 
our prior findings, we observed greater recruitment of 
DNA-PK at LTR upon reactivation of latent proviral. In 
parallel to DNA-PK, we also noticed higher recruitment 
of RNAP II and co-recruitment of other transcription 
factors, such as NF-κB and P-TEFb at LTR, which clearly 
indicates enhanced ongoing transcription from LTR. 
Simultaneously, we found accumulation of euchromatic 
marks, such as acetylation of core histones (H3-AC), but 
removal of heterochromatic marks and enzymes involved, 
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such as H3K27me3 and of HDAC3. All of these changes 
facilitate the establishment of transcriptionally active 
euchromatin structures at HIV LTR, which support HIV 
transcription. However, upon inhibition of DNA-PK, the 
whole process gets reversed, and we noted the loss of 
euchromatic marks and accumulation of heterochromatic 
marks at HIV LTR, which leads to the generation of 
transcriptionally repressive heterochromatin structures 
at HIV LTR. Heterochromatin structures suppress 
transcription by impeding the access of transcription 
machinery as confirmed by reduced levels of RNAP II and 
other transcription factors at LTR.
Next, we investigated how DNA-PK promotes 
HIV transcription by regulating TRIM28 activity 
(Figure 10). Recently, TRIM28 was confirmed as one 
of the factors that facilitate RNAP II pausing at several 
cellular genes, including HIV [39, 42]. DNA-PK has 
been shown to interact directly with TRIM28 and 
catalyze the TRIM28 phosphorylation at serine 824 
residue, p-TRIM28-(S824) [37, 39]. This modification 
makes TRIM28 functionally active and converts it from 
a transcriptionally pausing factor to a transcriptionally 
active factor, which allows the release of paused 
RNAP II and promotes transcriptional elongation [37, 
39]. Thus, like SPT5 a component of another pausing 
factor DSIF complex, TRIM28 first promotes RNAP 
II pausing. However after phosphorylation at S824, it 
becomes activator of transcription and facilitates the 
release of paused RNAP II [39, 40]. We showed that 
TRIM28 is indeed the substrate of DNA-PK, as specific 
inhibition or depletion of DNA-PK resulted in reduced 
phosphorylation of TRIM28 at S824. However, during this 
study we noted that the P-TEFb inhibitor, 5,6-Dichloro-
1-beta-D- ribofuranosylbenzimidazole (DRB) does not 
affect TRIM28 phosphorylation, suggesting that TRIM28 
S824 phosphorylation is not mediated by P-TEFb (not 
shown). The data suggest that reduced phosphorylation 
of TRIM28, upon DNA-PK inhibition or depletion, 
stabilizes the pausing state of RNAP II and contributes 
to decreased HIV transcription. Subsequently, in ChIP 
assays, in parallel to DNA-PK recruitment at LTR, 
we found the enhanced recruitment of TRIM28 and 
phosphorylated TRIM28 (S824) at HIV LTR. Specifically, 
at the Nuc-2 region of LTR, we noticed relatively higher 
fold enrichment of p-TRIM28 (S824) after stimulation 
with TNF-α. The accumulation of p-TRIM28 (S824) 
marks the presence of the transcription-supporting form 
of TRIM28 and thus indicates the transformation of 
paused RNAP II into a processive elongating RNAP II. 
Following DNA-PK depletion, we found very limited 
levels of p-TRIM28 (S824) at LTR, even after activation, 
demonstrating that DNA-PK is the main kinase that 
catalyzes the phosphorylation of TRIM28. However, 
besides DNA-PK, ATM has also been shown to catalyze 
the phosphorylation of TRIM28 at S824 [38, 79, 80]. It 
should be noted that following DNA-PK knockdown, we 
found reduced presence of both TRIM28 and p-TRIM28 
(S824) at LTR, clearly suggesting a primary role of DNA-
PK in the recruitment of TRIM28 at HIV LTR. It appears 
that ATM cannot compensate for the lack of this activity 
of DNA-PK. The detailed investigation of this important 
mechanism is a subject for future investigations utilizing 
a combination of biochemical, genetic, and genomics 
approaches.
We also evaluated the effect of the DNA-PK 
inhibitors NU7026 and NU7441 on HIV-1 replication in 
MT-4 cells, using a prototypical replication competent ×4 
variant of HIV-1 (HIV-1 X4LAI.04). Both inhibitors were 
able to completely inhibit HIV replication at low doses 
(Figure 10A and 10B) and were well-tolerated by the cells 
(Figure 10C and 10D).
Finally, we evaluated the clinical relevance of the 
DNA-PK inhibitor NU7441 by assessing its impact in 
restricting the reactivation of latent provirus in PBMCs 
from HIV-infected patients (Figure 11). We found an 
almost complete block of HIV gene expression in the 
cells treated with NU7441, even after stimulation of 
latently infected cells with α-CD3/CD28 antibodies. 
Notably, HAART treatment, which is highly successful 
in controlling HIV replication, was not effective in 
controlling HIV gene expression of the reactivated latent 
provirus. These results strongly argue for the inclusion 
of transcriptional inhibitors, such as DNA-PK inhibitors, 
as a supplement to HAART regimens for suppressing 
transient reactivation of latent proviruses. While 
continuous treatment with HAART prevents the infection 
of neighboring cells, in sanctuary sites, including gut-
associated lymphoid tissue (GALT) and central nervous 
system (CNS), the transient episodes of viral activation 
can lead to spread of viral reservoir and contribute to 
immune activation.
Thus, our findings unraveled the molecular 
mechanisms utilized by DNA-PK to enhance HIV 
transcription and confirmed the physiological relevance 
of DNA-PK inhibitors in restricting HIV gene expression, 
replication, and reactivation of latent provirus. We 
propose a model to depict these multiple activities of 
DNA-PK (Figure 12). Briefly, our data suggest that 
DNA-PK enhances HIV transcription by supporting 
the initiation phase of transcription by catalyzing the 
phosphorylation of RNAP II CTD at Ser5. By catalyzing 
the phosphorylation of TRIM28, specifically at residue 
S824, DNA-PK converts TRIM28 from a pausing factor 
to an elongating factor, thus relieving RNAP II pausing. 
Additionally, DNA-PK supports the elongation phase 
of HIV transcription by enhancing the processivity of 
RNAP II through augmenting the CTD phosphorylation 
at Ser2, both directly and via facilitating the recruitment of 
P-TEFb at HIV LTR. Consequently, by repressing all these 
pathways, DNA-PK inhibitors show a profound effect on 
HIV replication and latent proviral reactivation. Overall, 
our results support the notion that supplementing cART 
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regimens with DNA-PK inhibitors may, besides restricting 
HIV replication and protein production, also target HIV-
associated malignancies.
MATERIALS AND METHODS
Reagents
DNA-PK Inhibitors: NU7026 (Cat. # S2893) 
and NU7441 (Cat. # S2638) from Selleckchem, 
while IC86621 (Cat. # 404009-40-1) from Sigma-
Aldrich, was purchased. Stock solutions were made 
in DMSO at 5 mM concentration. DNA-PKcs shRNA 
vectors (Cat # sc-35200-SH) were purchased from 
Santa Cruz Biotech. In some experiments, we also 
used the lentiviral vector pHR’Sin-Puro with shRNA, 
which carry puromycin resistance gene and expresses 
shRNA through H1 Pol-III promoter. The shRNAs to 
DNA-PKcs (5′-GAACACTTGTACCAGTGTT-3′) or 
(5′-GATCGCACCTTACTCTGTT-3′) and scrambled 
control (5′-TTGATGCACTTACTAGATTAC-3′), were 
cloned. A total of 4 to 6 μg of VSV-G pseudotyped 
lentiviral vectors carrying specific or control shRNA were 
used for knockdown.
Cell culture conditions
The latently infected cell lines, J1.1 and U1 were 
obtained from AIDS Research and Reference Reagent 
Program, Division of AIDS, National Institute of Allergy 
and Infectious Diseases, U.S. National Institutes of 
Health (NIH). The Jurkat, THP-1, U937, and MT-4 cell 
lines were obtained from  ATCC, Manassas, VA, USA. 
However, primary T cells and PBMCs were isolated from 
blood in our lab. All these cells were cultured in RPMI 
medium with l-glutamine (Invitrogen), 10% fetal bovine 
serum (FBS), penicillin (100 IU/ml), Ciprofloxacin (10 
µM) and streptomycin (100 µg/ml). Primary cells were 
also supplied with primocin (invivoGen), 25 mM HEPES 
(pH 7.2) and IL-2 (20 U/ml of recombinant human IL-2 
[R&D Systems, Inc. or Roche]). The cells were grown in 
incubator maintaining CO2 at 5% and temperature at 37°C.
Cell lines and viruses
THP-1, Jurkat and primary cells were infected with 
replication-incompetent HIV (pHR’P-Luc, pHR’-PNL-
wildTat-d2GFP or pHR’-PNL-H13LTat-d2GFP), carrying 
reporter genes either luciferase or GFP under the control 
of the HIV LTR promoter. VSV-G-pseudotyped HIV 
particles were packaged as previously described. The 
latently infected promonocytic U1 and T-lymphocytic J1.1 
cell line harbor integrated replication-competent latent 
provirus and constitutively express very low amounts 
of HIV proteins. The primary cells were infected with 
replication-competent HIV-1 NL4-3 and ×4LAI.04 using 
standard protocol [81]. The cell viability was regularly 
evaluated by propidium iodide staining.
Luciferase assay
THP-1-pHR’-P-Luc, Jurkat-pHR’-P-Luc and 
primary CD4+ T cells were plated in 6-well plates 
at a concentration 106 cells/ml, in complete RPMI 
medium. The cells were pre-incubated with different 
concentrations of DNA-PK inhibitors or with dimethyl 
sulfoxide (DMSO) as control, overnight. Since the 
inhibitors were dissolved in DMSO, a set of cells was 
treated with the highest used concentration of DMSO 
as negative/background control. Next day, cells were 
supplied with fresh media containing inhibitors. The 
latent HIV provirus in the Jurkat and THP-1 cell lines 
was reactivated by treatment with Tumor Necrosis 
Factor alpha (TNF-α, 10 ng/ml), whereas in primary 
CD4+ T cells by stimulation through T cell receptor 
(TCR) with α-CD3/CD28 antibodies-coated beads (25 
μl/106 cells). After 48 hours, the cells were harvested 
and washed three times with phosphate-buffered saline 
(PBS). Subsequently, Bradford assays (Bio-Rad) were 
performed and equal amount of cell extracts were used 
in each luciferase reaction. Luciferase levels in the cells 
were assessed using a Promega commercial kit (Cat# 
E4530; Madison, WI, USA). Briefly, the cells were lysed 
for 30 minutes at room temperature with passive lysis 
buffer and centrifuged at 14000 rpm for 2 minutes. 5 µl 
of samples were added to individual wells of a 96-well 
plate, followed by 70 µl of luciferase substrate/assay 
buffer. Samples were tested in triplicate. Luminescence 
was read in a Microplate Luminometer (Bio-Rad or 
Turner Biosystems).
Cell cytotoxicity: MTS assay and MTT assay
The cytotoxicity of DNA-PK inhibitors in Jurkat, 
THP-1 and primary CD4+ T cells carrying pHR’P-
Luc, was assessed using 3-(4,5-dimethylthiazol-2-yl)-
5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium (MTS) reagent (Promega) following the 
supplier’s protocol. Briefly, the cells were seeded (3 × 103 
cells/ well) in 96-well plates and incubated with increasing 
concentrations of NU7441 or NU7026 for 5 days. Then 
the cells were incubated for 4 hours with the MTS reagent 
directly added in the culture wells. Subsequently, the 
optical density was measured at 490 nm, using a visible 
light 96-well plate reader.
The cytotoxicity of DNA-PK inhibitors in MT-4 
cells was evaluated with 3-(4, 5-dimethylthiazolyl-2)-2, 
5-diphenyltetrazolium bromide (MTT) reagent (Sigma-
Aldrich). The cells were pre-treated for 24 hours with the 
DNA-PK inhibitors NU7026 and NU7441 at different 
concentrations and DMSO as control, and seeded (2 × 104 
cells/well) in 96-well plate in 100 µl of RPMI 10% FBS. 
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The day after the cells were infected with ×4LAI.04, they 
were washed two times in PBS and plated again in a 96-
well plate. After 3 days, the MT-4 were incubated for 2 
hours at 37°C with MTT reagent, then treated with 100 µl 
of DMSO per well for 30 minutes and the optical density 
was measured at 570 nm in a plate reader.
HIV replication assay
U1, J1.1, and CD4+T cells were pre-treated overnight 
with multiple concentrations of DNA-PK inhibitors, 
prior to stimulation with 10 ng/ml of TNF-α for 56 hours 
more. HIV replication was determined by the reverse 
transcriptase (RT) assay as previously described in [82]. 
Briefly, the cell supernatants were incubated overnight at 
37°C with RT buffer (1 mM DTT, 5 mM MgCl2, 50 mM 
Tris-HCL, 20 mM of KCl, poly A, poly (dT), 0.1% Triton 
and [3H] TTP). The samples were then spotted on DEAE 
Filter mat paper and washed with 5% disodium phosphate 
(Na2HPO4) and water. The samples were dried completely, 
and the activity was read in a Betaplate counter (Wallac, 
Gaithersburg, MA, USA).
For replication assay in MT-4 cells, the cells were pre-
treated for 24 hours with the DNA-PK inhibitors NU7026 or 
NU7441 at different concentrations and DMSO as control, 
and seeded (105 cells/well) in 24 well plate in 1 ml of RPMI 
10% FBS. Next day, the cells were infected with 10 µL of 
viral stock ×4LAI.04 (0.7-ng/mL p24gag antigen) with ×4LAI.04 
and culture medium was replaced with fresh RPMI with 
DNA-PK inhibitors. Thus, inhibitors were present during 
the entire culture period. After 3 days, HIV-1 replication in 
MT-4 was evaluated by measuring the levels of p24gag in 
cell culture medium using a dynamic immunofluorescent 
cytometric bead assay (Luminex).
Western blot
Jurkat, and U937 cells (wild-type or DNA-PK 
knockdown) were plated at 5 × 106/ml in Petri dishes. 
The wild-type cells were incubated with 8 µM, 12 µM 
and 16 µM of NU7441 overnight. Cells were lysed 
with 0.5% NP-40 (supplemented with 10 mM HEPES-
KOH pH 7.9, 60 mM KCL, 1 mM EDTA, 1 mM DTT, 
1 mM phenylmethylsulfonylfluoride (PMSF), 10 μg/mL 
leupeptin, 10 μg/mL aprotinin. The isolated nuclei were 
then lysed in a buffer comprising 250 mM Tris pH7.8, 
60 mM KCL, 1 mM EDTA, 1 mM DTT, 1 mM PMSF, 
10 μg/mL leupeptin, 10 μg/mL aprotinin, 100 mM NaF, 
and 200 µM sodium orthovanadate with three freeze-thaw 
cycles. Protein samples were separated by electrophoresis 
in SDS-PAGE, transferred to a nitrocellulose membrane 
and detected with specific antibodies. The immunoreactive 
proteins, after incubation with appropriately labeled 
secondary antibodies, were detected with an enhanced 
chemiluminescence detection kit. Densitometric analysis 
was done with ImageJ software.
Reverse transcriptase-(RT)-qPCR
Total RNA was isolated from cells using a High 
Pure RNA Isolation Kit (Roche) or Trizol (ThermoFisher). 
The mRNA was reverse transcribed into complementary 
DNA (cDNA) using OneTaq RT-PCR Kit (New England 
Biolabs) or oligo dT primer. cDNA was quantified via 
Real-time quantitative PCR (RT-qPCR), which was 
performed in CFX96 Real-time PCR detection system 
(Bio-Rad) using SYBR green reaction mix (Bio-Rad). 
The data were normalized to the corresponding values for 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH). 
The Nuc-2 primer sequences are described in the ChIP 
section.
Chromatin immunoprecipitation (ChIP) assays 
and q-PCR
ChIP assays were performed using a previously 
described protocol [8, 60]. For cell stimulation, we either 
used 10 ng/ml TNF-α (for cell lines) or 25 μl per 106 cells 
of α-CD3/CD28 antibodies bound Dynal beads along with 
20 U/ml of IL-2 (for primary T cells). The chromatin was 
immunoprecipitated using different antibodies, detailed in 
the antibodies section. Each sample (5%) was analyzed 
by quantitative real-time PCR (qPCR) to assess the 
amount of sample immunoprecipitated by an individual 
antibody. Control preimmune IgG value was subtracted 
from each sample value to remove the background counts. 
SYBR green PCR master mix (12.5 μl/sample; Bio-Rad) 
combined with 1 μl of each primer, 5 μl of ChIPed DNA 
and water to a final volume 25 μl was analyzed by q-PCR. 
The primers used were the following (numbered with 
respect to the transcription start site): Promoter region of 
HIV-1 LTR (promoter) forward,–116, AGC TTG CTA CAA 
GGG ACT TTC C and reverse +4, ACC CAG TAC AGG 
CAA AAA GCA G; Nucleosome-1 region HIV-1 LTR (Nuc-
1) forward +30, CTG GGA GCT CTC TGG CTA ACT A 
and reverse +134, TTA CCA GAG TCA CAC AAC AGA 
CG; Nucleosome-2 region HIV-1 LTR (Nuc-2) forward 
+283F, GACTGGTGAGTACGCCAAAAAT and reverse 
+390R, TTTCCCATCGCGATCTAATTC glyceraldehyde 
3-phosphate dehydrogenase (GAPDH) promoter forward, 
–125, CAC GTA GCT CAG GCC TCA AGA C and reverse, 
–10, AGG CTG CGG GCT CAA TTT ATA G; GAPDH was 
also assessed by forward, –145, TAC TAG CGG TTT TAC 
GGG CG and reverse, +21 TCG AAC AGG AGG AGC 
AGA GAG CGA.
Antibodies
The following antibodies where used in this study: 
RNAP II (17-672, Millipore; 61667, Active Motif; or 
sc-899, Santa Cruz), p-RNAP II (Ser2) (13499, Cell 
Signaling; 3E10, Active Motif, ab5095, Abcam), p-RNAP 
II (Ser5) (61085, Active Motif; 13523, Cell Signaling), 
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H3-Ac (Upstate 07-593), H3K27me3 (07-449; Upstate), 
DNA-PKcs (Sc-9051, Santa Cruz), p-DNA-PKcs (S2056) 
(ab18192, Abcam), TRIM28 (A300-274A, Bethyl), 
p-TRIM28 (S824) (A300-767A, Bethyl), Tat (ab6539, 
Abcam), Cyclin T1 (sc-8128, Santa Cruz), p65 (sc-372 
and sc-514451 Santa Cruz), CDK9 (sc-13130, sc-484), 
CDK7 (A300-405A, Bethyl), HDAC1 (sc-7872 and sc-
6298, Santa Cruz), HDAC3 (sc-11417 and sc-376957 
Santa Cruz), β-Actin (sc-47778 Santa Cruz).
Flow cytometric analysis
Jurkat and U937 cells and corresponding DNA-PK 
knockdown clones were infected with VSV-G pseudotyped 
replication-incompetent HIV carrying GFP gene. After 
48 to 72 hours, the expression of the fluorescent reporter, 
GFP, was assessed through fluorescence-activated cell 
sorting (FACS) using a FACSCalibur flow cytometer. Data 
were analyzed using Flowjo software.
Statistical analysis
Data were analyzed using Microsoft Excel or 
GraphPad Prism and ImageJ softwares. For paired samples, 
statistical analyses were performed using Student’s t test. 
Statistical comparisons between the control and tested 
groups were analyzed using the one-way ANOVA. The p 
value of statistical significance was set at either; p < 0.05 
(*), 0.01 (**), 0.001 (***), or 0.0001 (****). All experiments 
were independently repeated at least three times.
CONCLUSIONS
Overall, our results reveal the important role of 
DNA-PK in supporting HIV transcription, replication, 
and latent proviral reactivation. By performing luciferase 
and reverse transcriptase assays, we demonstrated that 
the restriction of DNA-PK activity via specific inhibitors 
strongly represses HIV transcription and viral replication, 
and confirmed these results not only in lymphoid and 
myeloid cell lines, but also in primary CD4+ T cells. 
Subsequently, by chromatin immunoprecipitation assays 
we showed that specific DNA-PK inhibitors repress HIV 
transcription by inducing transcriptionally repressive 
chromatin structures at HIV LTR, and they inhibit both 
the initiation and elongation phases of HIV transcription 
by severely restricting the phosphorylation of the carboxyl 
terminal domain (CTD) of RNAP II.
Given that the transcriptional block plays a major 
role in sustaining HIV proviruses in the latent state, 
this study sheds light on an important pathway that 
regulates HIV latency. Moreover, these results support a 
potential therapeutic use of specific DNA-PK inhibitors 
as supplements in HAART/cART regimens to further 
enhance the effectiveness of anti-HIV therapy and might 
even control the rate of HIV-associated cancers, as DNA-
PK inhibitors are under trial for cancer therapy.
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